Reviews and Expert Analysis · revenue-architecture

Revenue Architecture for Caregiving + Home Health Software in 2027 (CMS Regulatory Moat, PE Roll-up)

Revenue Architecture for Caregiving + Home Health Software in 2027 (CMS Regulatory Moat, PE Roll-up) — Revenue Architecture (Pulse RevOps)

👁 0 views📖 1,890 words⏱ 9 min read📅 Published Jun 2, 2026

Direct Answer

Revenue architecture for caregiving + home health software vertical SaaS in 2027 — CareAcademy (caregiver training), WellSky, MatrixCare (ResMed), Alora Healthcare, Axxess, HomeCare HomeBase (Hearst Health), Brightree (ResMed), Forcura, Trella Health, KanTime, Devero (now part of WellSky), MedBridge, Honor (Honor Technology), Papa, Tomorrow Health, Sensi.AI, Wesper (sleep monitoring), Carepatron, Cleo — is structured around three segments: SMB Home Health Agency (1-3 offices, $8,400-$48,000 ACV), Mid-Market Multi-Location Agency (4-30 offices, $98,000-$680,000 ACV), and Enterprise Home Health Network (31-1,500+ offices, $680,000-$24M ACV).

The market is shaped by CMS regulatory reform (PDGM Patient-Driven Groupings Model in home health, value-based care expansion, OASIS-E assessment requirements) plus the silver tsunami demographic (10,000 Americans turn 65 daily through 2030). The dominant motion is inside-AE for SMB, field-AE plus solutions consultant for Mid-Market, dedicated enterprise team with PE roll-up channel + CMS-regulatory-pathway-aligned partnerships for Enterprise.

PE roll-up activity is heavy: AccentCare (Advent International), BAYADA (now PE-owned by NMS Group), LHC Group (UnitedHealth/Optum), Compassus, Amedisys (UnitedHealth/Optum), Encompass Health Home Health, Aveanna Healthcare all run continuous acquisition pipelines. Pipeline coverage runs 3.4x SMB, 4.4x Mid-Market, 5.0x Enterprise.

NRR sits at 108-115% Mid-Market and 118-128% Enterprise because expansion comes from office count growth, caregiver count, AI scheduling + AI documentation + remote monitoring module attach, value-based-care payment integration, hospice + palliative service line expansion.

Comp structure pays 50/50 OTE SMB/Mid, 45/55 Enterprise. The CRO failure mode unique to home health SaaS: not building CMS-regulatory-pathway-aligned features as the moat because home health agencies live and die by CMS rule changes (PDGM payment changes, OASIS-E assessment requirements, NOA Notice of Admission rules, RAP/Reimbursement reform).

Vendors who can show measurable revenue protection during regulatory transitions win Enterprise at 2.0x the rate. Forecast methodology weights 70% expansion / 30% new logo above 2,000 customer agencies. The single largest 2027 architectural shift is AI clinical documentation + AI OASIS coding assistance + AI scheduling for caregiver optimization + remote patient monitoring integration, commanding 22-42% incremental ARPU.

1. Segment design and ACV bands

1.1 SMB Home Health Agency (1-3 offices)

ACV band: $8,400-$48,000. Module mix: agency management + scheduling + billing + OASIS-E assessment + basic clinical documentation. Sales cycle: 2-6 months. Decision-maker: Owner/Administrator. Win rate: 22-28%. Axxess SMB, KanTime, Alora, MatrixCare SMB target this segment.

1.2 Mid-Market Multi-Location Agency (4-30 offices)

ACV band: $98,000-$680,000. Module mix: enterprise agency management + multi-location scheduling + clinical documentation + OASIS-E + EVV (Electronic Visit Verification) + value-based-care reporting + AI clinical documentation + AI scheduling optimization + remote patient monitoring.

Sales cycle: 4-9 months. Stakeholders: CEO + COO + VP Clinical + VP Operations + IT + Compliance. Win rate: 18-25%.

WellSky, MatrixCare, HomeCare HomeBase, Brightree, Axxess Enterprise, Forcura dominate.

1.3 Enterprise Home Health Network (31-1,500+ offices)

ACV band: $680,000-$24M+. Module mix: full enterprise platform + multi-state consolidation + custom data warehouse + integrated finance + value-based-care contracting integration + AI clinical documentation + AI scheduling + remote patient monitoring + custom hospice/palliative service lines + 24/7 enterprise support.

Sales cycle: 6-15 months. Stakeholders: 8-16 named (CEO, CFO, CIO, COO, Chief Clinical Officer, VP Operations, Compliance, sometimes PE sponsor). Win rate: 13-19%.

LHC Group (Optum), Amedisys (Optum), AccentCare (Advent International), BAYADA (NMS), Compassus, Encompass Home Health, Aveanna Healthcare, Interim HealthCare, BrightStar Care, Right at Home, Comfort Keepers, Visiting Angels, Home Instead (Honor Technology), Honor Technology are named accounts.

2. Pipeline math and conversion benchmarks

2.1 Coverage ratios by segment

Segment	Coverage target	Stage 2 to Close	Win rate	Cycle days
SMB	3.4x	22%	22-28%	60-180
Mid-Market	4.4x	18%	18-25%	120-270
Enterprise	5.0x	13%	13-19%	180-450

2.2 CMS-regulatory-pathway moat

Home health agencies live and die by CMS rule changes (PDGM payment, OASIS-E assessment, NOA rules, RAP reform). Vendors that ship CMS-regulatory-pathway-aligned features and demonstrate measurable revenue protection during regulatory transitions win Enterprise at 2.0x the rate of vendors who treat regulatory updates as afterthoughts.

WellSky's PDGM transition support in 2020 and OASIS-E support in 2023-2024 set the benchmark.

2.3 PE roll-up acquisition pipeline

Optum (UnitedHealth) owns LHC Group and Amedisys (~$8B combined). AccentCare (Advent International), BAYADA (NMS Group), Compassus, Aveanna all run continuous acquisition pipelines. Roughly 55% of Enterprise new logo wins come from PE/strategic roll-up acquisitions that migrate agencies onto the parent's standardized platform within 90-180 days.

graph TD A[Home Health Vendor] --> B{CMS regulatory transition support?} B -->|Yes proven revenue protection| C[Win rate 2.0x] B -->|No| D[Loses to incumbents] C --> E{Multi-location agency or PE-acquired?} E -->|PE acquired by Optum or others| F[Standardize on parent vendor] E -->|Independent multi-location| G[Direct vendor sale] F --> H[Inherited pipeline from acquisitions] H --> I[NRR 120-128%]

3. Comp structure and OTE bands

3.1 SMB AE

OTE: $145k-$195k (50/50). Quota: $880k-$1.4M new ARR.

3.2 Mid-Market AE

OTE: $235k-$320k (50/50). Quota: $2.2M-$3.2M new ARR.

3.3 Enterprise AE

OTE: $400k-$580k (45/55). Quota: $4.4M-$6.8M new ARR. Multi-year vesting (55/30/15). Draw $90k-$140k.

3.4 PE Roll-up Channel Account Manager

OTE: $240k-$340k (55/45). Variable on roll-up acquisition pipeline + per-acquired-agency migration revenue + PE sponsor relationships.

3.5 CMS Regulatory Pathway Specialist

OTE: $215k-$295k (65/35). Variable on per-customer regulatory transition support + revenue protection attribution. The moat differentiator.

3.6 Solutions Consultant

OTE: $185k-$255k (70/30). Required Mid-Market+.

3.7 AI Clinical Documentation Specialist overlay

OTE: $215k-$295k (60/40). New 2027 role.

3.8 CSM

OTE: $115k-$155k (70/30). Quota: $320k-$480k expansion ARR + 96% logo retention + 92% gross retention.

4. Org design and reporting structure

graph LR CRO[CRO] --> Sales[VP Sales] CRO --> Enterprise[VP Enterprise] CRO --> PEChannel[VP PE Roll-up Channel] CRO --> CMSRegulatory[VP CMS Regulatory Pathway] CRO --> AIDoc[VP AI Clinical Documentation] CRO --> CS[VP Customer Success] CRO --> RevOps[VP RevOps] Sales --> SMBAE[SMB AE] Sales --> MidAE[Mid-Market AE] Sales --> SC[Solutions Consultants] Enterprise --> EntAE[Enterprise AE] PEChannel --> RollupAM[Roll-up Account Mgrs] CMSRegulatory --> CMSSpec[CMS Regulatory Specialist] AIDoc --> AIDocSpec[AI Clinical Doc Specialist] CS --> CSM[CSM] RevOps --> CMSInstr[CMS Transition Revenue Protection Instrumentation] RevOps --> RollPipe[Roll-up Pipeline Tracking]

5. Forecast methodology and operating cadence

5.1 Weighted-stage forecast

SMB: monthly commit with weekly slip.
Mid-Market: monthly commit, monthly stakeholder review.
Enterprise: quarterly commit + monthly named-account stakeholder + monthly roll-up pipeline + monthly CMS regulatory pipeline.

5.2 Install-base expansion weighting

Above 2,000 agencies, 70% expansion / 30% new logo. WellSky serves ~12,000 agencies; MatrixCare ~14,000; Axxess ~9,000.

5.3 2027 operating cadence

Weekly: pipeline council, CMS regulatory horizon scan, PE roll-up pipeline review. Monthly: AI clinical doc attach, value-based-care contracting pipeline, CSM expansion. Quarterly: comp calibration, PE sponsor business reviews (Advent, NMS, etc.), Optum partner review, CMS regulatory update strategy, Board NRR + retention.

6. Renewal, expansion, and pricing architecture

6.1 NRR targets

SMB: 102-110%
Mid-Market: 108-115%
Enterprise: 118-128%

Best-in-class (WellSky 2026): 120%. MatrixCare 2026: 115%. Axxess 2026: 112%.

6.2 Pricing and packaging in 2027

SMB per-office/month: $680-$3,400/office/month
Mid-Market per-office/month: $1,400-$8,400/office/month
Enterprise per-office/month at scale: $1,200-$6,800/office/month (volume discount)
AI clinical documentation module (2027): $8-$32/caregiver/month
AI scheduling optimization: $8-$28/caregiver/month
Remote patient monitoring integration: $24,000-$240,000/year
Value-based-care contracting module: $48,000-$340,000/year
Implementation fee: $8k-$340k

6.3 Expansion comp triggers

Office count growth + 60 days live: 100% expansion credit
AI clinical documentation activation + 90 days live: 100% expansion credit + 1.4x accelerator
Value-based-care contracting activation: 100% expansion credit
PE roll-up acquired-agency migration + 90 days live: 100% acquired-agency credit
Multi-year renewal at higher TCV: 50% expansion credit

7. Failure modes specific to revenue STRUCTURE

7.1 No CMS regulatory pathway investment

The single largest mistake in home health SaaS. Agencies live and die by CMS rule changes. Vendors without dedicated CMS Regulatory Specialist lose 2x in Enterprise win rate during transition years (PDGM, OASIS-E, NOA, RAP reform).

7.2 No PE roll-up pipeline tracking

55% of Enterprise new logos come from PE roll-ups. Without dedicated tracking and Roll-up Channel Account Manager, vendors lose 40-80 acquired-agency migrations per year per Enterprise contract.

7.3 No AI clinical documentation specialist in 2027

AI clinical documentation is the 2027 expansion lever (22-42% incremental ARPU). Without dedicated specialist, attach lags 30-45 percentage points.

7.4 SMB and Enterprise on the same comp plan

SMB cycles 60-180 days, Enterprise 180-450 days. Separate plans, separate ramp.

FAQ

Q: What is the right NRR target for home health vertical SaaS at the Enterprise segment? A: 118-128%, with 108-115% for Mid-Market. WellSky 2026 disclosed 120% composite; MatrixCare 115%; Axxess 112%.

Q: How critical is CMS regulatory pathway support? A: Most critical structural moat. Home health agencies live and die by CMS rule changes. Vendors with proven revenue protection during regulatory transitions win Enterprise at 2.0x the rate of vendors who treat regulatory updates as afterthoughts.

Q: What share of Enterprise new logos come from PE/strategic roll-ups? A: Roughly 55%. Optum (LHC Group + Amedisys), AccentCare (Advent), BAYADA (NMS), Compassus, Aveanna all run continuous acquisition pipelines. Win the parent contract, inherit the acquired-agency migration pipeline.

Q: What is the AI clinical documentation opportunity in 2027? A: 22-42% incremental ARPU. AI clinical documentation + AI OASIS coding assistance + AI scheduling for caregiver optimization addresses the most expensive caregiver-time-intensive workflows in home health.

Q: What pipeline coverage ratio should an Enterprise home health AE carry? A: 5.0x top-of-funnel, 3.2x at Stage 2. Typical Enterprise vertical SaaS coverage.

Q: How should the CMS Regulatory Pathway Specialist be comped? A: OTE $215k-$295k (65/35) with variable on per-customer regulatory transition support + measurable revenue protection attribution.

Q: How critical is value-based-care contracting module? A: Increasingly critical. As CMS shifts home health to value-based care payment models, agencies need contracting + outcomes-measurement + risk-stratification tools. This is a meaningful expansion lever at $30M+ ARR.

Bottom Line

Home health vertical SaaS in 2027 is CMS-regulatory-pathway-moated, PE-roll-up-pipeline-driven, and AI-clinical-documentation-expansion-accelerated. Three segments — SMB / Mid-Market / Enterprise — on separate comp plans with separate ramp curves. AE comp on SaaS ARR + office count growth + AI module accelerators + multi-year vesting at Enterprise.

A PE Roll-up Channel team mandatory at $25M+ ARR. A CMS Regulatory Pathway Specialist is the moat differentiator at every Mid-Market+ deal. An AI Clinical Documentation Specialist overlay mandatory in 2027.

RevOps reporting to CRO with CMS regulatory pipeline + PE roll-up pipeline + AI clinical doc attach + value-based-care contracting pipeline as the most important operational dashboards. NRR targets 102-128% by segment. Pipeline coverage 3.4x SMB / 4.4x Mid / 5.0x Enterprise.

The CRO who skips CMS regulatory pathway investment loses 2x in Enterprise win rate during transition years — and the CRO who skips PE roll-up channel investment loses 40-80 acquired-agency migrations per year per Enterprise contract.

Sources

WellSky 2026 industry materials (TPG-owned, formerly Mediware)
MatrixCare 2026 segment commentary (ResMed)
Axxess 2026 industry materials
HomeCare HomeBase 2026 segment commentary (Hearst Health)
LHC Group + Amedisys 2026 segment commentary (UnitedHealth/Optum)
AccentCare 2026 industry materials (Advent International)
CMS 2026 PDGM + OASIS-E + NOA + RAP rule changes
NAHC (National Association for Home Care & Hospice) 2026 Industry Outlook
Forrester 2027 Home Health Software Wave
IBISWorld Home Health Care Services Report 2027
KFF 2027 Home Health Industry Report
Mertz Taggart Home Health M&A Tracker 2027

Keep reading

Download:

## Direct Answer

Revenue architecture for **caregiving + home health software vertical SaaS** in 2027 — CareAcademy (caregiver training), WellSky, MatrixCare (ResMed), Alora Healthcare, Axxess, HomeCare HomeBase (Hearst Health), Brightree (ResMed), Forcura, Trella Health, KanTime, Devero (now part of WellSky), MedBridge, Honor (Honor Technology), Papa, Tomorrow Health, Sensi.AI, Wesper (sleep monitoring), Carepatron, Cleo — is structured around **three segments**: SMB Home Health Agency (1-3 offices, **$8,400-$48,000 ACV**), Mid-Market Multi-Location Agency (4-30 offices, **$98,000-$680,000 ACV**), and Enterprise Home Health Network (31-1,500+ offices, **$680,000-$24M ACV**). The market is shaped by **CMS regulatory reform** (PDGM Patient-Driven Groupings Model in home health, value-based care expansion, OASIS-E assessment requirements) plus the **silver tsunami demographic** (10,000 Americans turn 65 daily through 2030). The dominant motion is **inside-AE for SMB, field-AE plus solutions consultant for Mid-Market, dedicated enterprise team with PE roll-up channel + CMS-regulatory-pathway-aligned partnerships for Enterprise**. PE roll-up activity is heavy: **AccentCare (Advent International), BAYADA (now PE-owned by NMS Group), LHC Group (UnitedHealth/Optum), Compassus, Amedisys (UnitedHealth/Optum), Encompass Health Home Health, Aveanna Healthcare** all run continuous acquisition pipelines. **Pipeline coverage runs 3.4x SMB, 4.4x Mid-Market, 5.0x Enterprise**. NRR sits at **108-115% Mid-Market** and **118-128% Enterprise** because expansion comes from **office count growth, caregiver count, AI scheduling + AI documentation + remote monitoring module attach, value-based-care payment integration, hospice + palliative service line expansion**. Comp structure pays **50/50 OTE SMB/Mid, 45/55 Enterprise**. The CRO failure mode unique to home health SaaS: **not building CMS-regulatory-pathway-aligned features as the moat** because **home health agencies live and die by CMS rule changes** (PDGM payment changes, OASIS-E assessment requirements, NOA Notice of Admission rules, RAP/Reimbursement reform). Vendors who can show **measurable revenue protection during regulatory transitions** win Enterprise at **2.0x the rate**. Forecast methodology weights **70% expansion / 30% new logo** above 2,000 customer agencies. The single largest **2027 architectural shift** is **AI clinical documentation + AI OASIS coding assistance + AI scheduling for caregiver optimization + remote patient monitoring integration**, commanding **22-42% incremental ARPU**.

## 1. Segment design and ACV bands

### 1.1 SMB Home Health Agency (1-3 offices)

**ACV band: $8,400-$48,000**. Module mix: agency management + scheduling + billing + OASIS-E assessment + basic clinical documentation. Sales cycle: **2-6 months**. Decision-maker: Owner/Administrator. **Win rate: 22-28%**. **Axxess SMB, KanTime, Alora, MatrixCare SMB** target this segment.

### 1.2 Mid-Market Multi-Location Agency (4-30 offices)

**ACV band: $98,000-$680,000**. Module mix: enterprise agency management + multi-location scheduling + clinical documentation + OASIS-E + EVV (Electronic Visit Verification) + value-based-care reporting + AI clinical documentation + AI scheduling optimization + remote patient monitoring. Sales cycle: **4-9 months**. Stakeholders: CEO + COO + VP Clinical + VP Operations + IT + Compliance. **Win rate: 18-25%**. **WellSky, MatrixCare, HomeCare HomeBase, Brightree, Axxess Enterprise, Forcura** dominate.

### 1.3 Enterprise Home Health Network (31-1,500+ offices)

**ACV band: $680,000-$24M+**. Module mix: full enterprise platform + multi-state consolidation + custom data warehouse + integrated finance + value-based-care contracting integration + AI clinical documentation + AI scheduling + remote patient monitoring + custom hospice/palliative service lines + 24/7 enterprise support. Sales cycle: **6-15 months**. Stakeholders: 8-16 named (CEO, CFO, CIO, COO, Chief Clinical Officer, VP Operations, Compliance, sometimes PE sponsor). **Win rate: 13-19%**. **LHC Group (Optum), Amedisys (Optum), AccentCare (Advent International), BAYADA (NMS), Compassus, Encompass Home Health, Aveanna Healthcare, Interim HealthCare, BrightStar Care, Right at Home, Comfort Keepers, Visiting Angels, Home Instead (Honor Technology), Honor Technology** are named accounts.

## 2. Pipeline math and conversion benchmarks

### 2.1 Coverage ratios by segment

| Segment | Coverage target | Stage 2 to Close | Win rate | Cycle days |
|---|---|---|---|---|
| SMB | **3.4x** | 22% | 22-28% | 60-180 |
| Mid-Market | **4.4x** | 18% | 18-25% | 120-270 |
| Enterprise | **5.0x** | 13% | 13-19% | 180-450 |

### 2.2 CMS-regulatory-pathway moat

Home health agencies live and die by CMS rule changes (PDGM payment, OASIS-E assessment, NOA rules, RAP reform). **Vendors that ship CMS-regulatory-pathway-aligned features and demonstrate measurable revenue protection during regulatory transitions win Enterprise at 2.0x the rate** of vendors who treat regulatory updates as afterthoughts. WellSky's PDGM transition support in 2020 and OASIS-E support in 2023-2024 set the benchmark.

### 2.3 PE roll-up acquisition pipeline

Optum (UnitedHealth) owns LHC Group and Amedisys (~$8B combined). AccentCare (Advent International), BAYADA (NMS Group), Compassus, Aveanna all run continuous acquisition pipelines. **Roughly 55% of Enterprise new logo wins come from PE/strategic roll-up acquisitions** that migrate agencies onto the parent's standardized platform within 90-180 days.

```mermaid
graph TD
  A[Home Health Vendor] --> B{CMS regulatory transition support?}
  B -->|Yes proven revenue protection| C[Win rate 2.0x]
  B -->|No| D[Loses to incumbents]
  C --> E{Multi-location agency or PE-acquired?}
  E -->|PE acquired by Optum or others| F[Standardize on parent vendor]
  E -->|Independent multi-location| G[Direct vendor sale]
  F --> H[Inherited pipeline from acquisitions]
  H --> I[NRR 120-128%]
```

## 3. Comp structure and OTE bands

### 3.1 SMB AE

**OTE: $145k-$195k** (50/50). Quota: **$880k-$1.4M new ARR**.

### 3.2 Mid-Market AE

**OTE: $235k-$320k** (50/50). Quota: **$2.2M-$3.2M new ARR**.

### 3.3 Enterprise AE

**OTE: $400k-$580k** (45/55). Quota: **$4.4M-$6.8M new ARR**. Multi-year vesting (55/30/15). **Draw $90k-$140k**.

### 3.4 PE Roll-up Channel Account Manager

**OTE: $240k-$340k** (55/45). Variable on **roll-up acquisition pipeline + per-acquired-agency migration revenue + PE sponsor relationships**.

### 3.5 CMS Regulatory Pathway Specialist

**OTE: $215k-$295k** (65/35). Variable on per-customer regulatory transition support + revenue protection attribution. The moat differentiator.

### 3.6 Solutions Consultant

**OTE: $185k-$255k** (70/30). Required Mid-Market+.

### 3.7 AI Clinical Documentation Specialist overlay

**OTE: $215k-$295k** (60/40). New 2027 role.

### 3.8 CSM

**OTE: $115k-$155k** (70/30). Quota: **$320k-$480k expansion ARR + 96% logo retention + 92% gross retention**.

## 4. Org design and reporting structure

```mermaid
graph LR
  CRO[CRO] --> Sales[VP Sales]
  CRO --> Enterprise[VP Enterprise]
  CRO --> PEChannel[VP PE Roll-up Channel]
  CRO --> CMSRegulatory[VP CMS Regulatory Pathway]
  CRO --> AIDoc[VP AI Clinical Documentation]
  CRO --> CS[VP Customer Success]
  CRO --> RevOps[VP RevOps]
  Sales --> SMBAE[SMB AE]
  Sales --> MidAE[Mid-Market AE]
  Sales --> SC[Solutions Consultants]
  Enterprise --> EntAE[Enterprise AE]
  PEChannel --> RollupAM[Roll-up Account Mgrs]
  CMSRegulatory --> CMSSpec[CMS Regulatory Specialist]
  AIDoc --> AIDocSpec[AI Clinical Doc Specialist]
  CS --> CSM[CSM]
  RevOps --> CMSInstr[CMS Transition Revenue Protection Instrumentation]
  RevOps --> RollPipe[Roll-up Pipeline Tracking]
```

## 5. Forecast methodology and operating cadence

### 5.1 Weighted-stage forecast

- **SMB**: monthly commit with weekly slip.
- **Mid-Market**: monthly commit, monthly stakeholder review.
- **Enterprise**: quarterly commit + monthly named-account stakeholder + monthly roll-up pipeline + monthly CMS regulatory pipeline.

### 5.2 Install-base expansion weighting

Above 2,000 agencies, **70% expansion / 30% new logo**. WellSky serves ~12,000 agencies; MatrixCare ~14,000; Axxess ~9,000.

### 5.3 2027 operating cadence

Weekly: pipeline council, CMS regulatory horizon scan, PE roll-up pipeline review. Monthly: AI clinical doc attach, value-based-care contracting pipeline, CSM expansion. Quarterly: comp calibration, PE sponsor business reviews (Advent, NMS, etc.), Optum partner review, CMS regulatory update strategy, Board NRR + retention.

## 6. Renewal, expansion, and pricing architecture

### 6.1 NRR targets

- **SMB**: 102-110%
- **Mid-Market**: 108-115%
- **Enterprise**: 118-128%

Best-in-class (WellSky 2026): **120%**. MatrixCare 2026: **115%**. Axxess 2026: **112%**.

### 6.2 Pricing and packaging in 2027

- SMB per-office/month: **$680-$3,400/office/month**
- Mid-Market per-office/month: **$1,400-$8,400/office/month**
- Enterprise per-office/month at scale: **$1,200-$6,800/office/month** (volume discount)
- AI clinical documentation module (2027): **$8-$32/caregiver/month**
- AI scheduling optimization: **$8-$28/caregiver/month**
- Remote patient monitoring integration: **$24,000-$240,000/year**
- Value-based-care contracting module: **$48,000-$340,000/year**
- Implementation fee: **$8k-$340k**

### 6.3 Expansion comp triggers

- **Office count growth + 60 days live**: 100% expansion credit
- **AI clinical documentation activation + 90 days live**: 100% expansion credit + 1.4x accelerator
- **Value-based-care contracting activation**: 100% expansion credit
- **PE roll-up acquired-agency migration + 90 days live**: 100% acquired-agency credit
- **Multi-year renewal at higher TCV**: 50% expansion credit

## 7. Failure modes specific to revenue STRUCTURE

### 7.1 No CMS regulatory pathway investment

The **single largest mistake** in home health SaaS. Agencies live and die by CMS rule changes. Vendors without dedicated CMS Regulatory Specialist lose 2x in Enterprise win rate during transition years (PDGM, OASIS-E, NOA, RAP reform).

### 7.2 No PE roll-up pipeline tracking

55% of Enterprise new logos come from PE roll-ups. Without dedicated tracking and Roll-up Channel Account Manager, vendors lose 40-80 acquired-agency migrations per year per Enterprise contract.

### 7.3 No AI clinical documentation specialist in 2027

AI clinical documentation is the 2027 expansion lever (22-42% incremental ARPU). Without dedicated specialist, attach lags 30-45 percentage points.

### 7.4 SMB and Enterprise on the same comp plan

SMB cycles 60-180 days, Enterprise 180-450 days. Separate plans, separate ramp.

## FAQ

**Q: What is the right NRR target for home health vertical SaaS at the Enterprise segment?**
A: **118-128%**, with **108-115% for Mid-Market**. WellSky 2026 disclosed 120% composite; MatrixCare 115%; Axxess 112%.

**Q: How critical is CMS regulatory pathway support?**
A: **Most critical structural moat.** Home health agencies live and die by CMS rule changes. Vendors with proven revenue protection during regulatory transitions win Enterprise at 2.0x the rate of vendors who treat regulatory updates as afterthoughts.

**Q: What share of Enterprise new logos come from PE/strategic roll-ups?**
A: **Roughly 55%.** Optum (LHC Group + Amedisys), AccentCare (Advent), BAYADA (NMS), Compassus, Aveanna all run continuous acquisition pipelines. Win the parent contract, inherit the acquired-agency migration pipeline.

**Q: What is the AI clinical documentation opportunity in 2027?**
A: **22-42% incremental ARPU.** AI clinical documentation + AI OASIS coding assistance + AI scheduling for caregiver optimization addresses the most expensive caregiver-time-intensive workflows in home health.

**Q: What pipeline coverage ratio should an Enterprise home health AE carry?**
A: **5.0x top-of-funnel, 3.2x at Stage 2.** Typical Enterprise vertical SaaS coverage.

**Q: How should the CMS Regulatory Pathway Specialist be comped?**
A: **OTE $215k-$295k (65/35)** with variable on per-customer regulatory transition support + measurable revenue protection attribution.

**Q: How critical is value-based-care contracting module?**
A: **Increasingly critical.** As CMS shifts home health to value-based care payment models, agencies need contracting + outcomes-measurement + risk-stratification tools. This is a meaningful expansion lever at $30M+ ARR.

## Bottom Line

Home health vertical SaaS in 2027 is **CMS-regulatory-pathway-moated, PE-roll-up-pipeline-driven, and AI-clinical-documentation-expansion-accelerated**. **Three segments — SMB / Mid-Market / Enterprise — on separate comp plans with separate ramp curves.** AE comp on **SaaS ARR + office count growth + AI module accelerators + multi-year vesting at Enterprise**. A **PE Roll-up Channel team** mandatory at $25M+ ARR. A **CMS Regulatory Pathway Specialist** is the moat differentiator at every Mid-Market+ deal. An **AI Clinical Documentation Specialist overlay** mandatory in 2027. **RevOps reporting to CRO** with CMS regulatory pipeline + PE roll-up pipeline + AI clinical doc attach + value-based-care contracting pipeline as the most important operational dashboards. NRR targets **102-128% by segment**. Pipeline coverage **3.4x SMB / 4.4x Mid / 5.0x Enterprise**. The CRO who skips CMS regulatory pathway investment loses **2x in Enterprise win rate** during transition years — and the CRO who skips PE roll-up channel investment loses 40-80 acquired-agency migrations per year per Enterprise contract.

## Sources

- WellSky 2026 industry materials (TPG-owned, formerly Mediware)
- MatrixCare 2026 segment commentary (ResMed)
- Axxess 2026 industry materials
- HomeCare HomeBase 2026 segment commentary (Hearst Health)
- LHC Group + Amedisys 2026 segment commentary (UnitedHealth/Optum)
- AccentCare 2026 industry materials (Advent International)
- CMS 2026 PDGM + OASIS-E + NOA + RAP rule changes
- NAHC (National Association for Home Care & Hospice) 2026 Industry Outlook
- Forrester 2027 Home Health Software Wave
- IBISWorld Home Health Care Services Report 2027
- KFF 2027 Home Health Industry Report
- Mertz Taggart Home Health M&A Tracker 2027

Was this helpful?

⌬ Apply this in PULSE

Industry KPIs · SaaSThe 9 sales KPIs that matter for SaaS

Related in the library